The Life Science industry is standing on the edge of a “patent cliff.” In 2015, the world’s biggest pharmaceutical firms stand to lose up to US$47.5 billion in revenues from the expiry of the patents of some of their biggest blockbuster drugs. For example, Celebrex – an arthritis drug which contributed almost US$3 billion to Pfizer’s revenues in 2014 – is set to see its patent expire later this year, opening it up to competition from “generic” alternatives which are often sold at much cheaper prices.
Accounting | Corporate Finance
Corporate Reporting and Disclosure
Navigating the “patent-cliff”: The role of corporate real estate in the life Science industry. (2015). Research Collection School Of Accountancy.
Available at: http://ink.library.smu.edu.sg/soa_research/1653
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.